Therapeutic Delivery – Products

Product News
Cyprumed Enters License and Option Agreement With MSD for the Development of Oral Peptide Therapeutics
Cyprumed and MSD have partnered to develop oral peptide formulations using Cyprumed’s drug delivery technology.

Product News
BOC Sciences Returns to Drug Discovery Chemistry 2025, Seeking Broad Partnerships
BOC Sciences adds to its participation agenda the prestigious Drug Discovery Chemistry 2025 Conference (April 14-17, 2025), which will be a hybrid event taking place in San Diego, CA, and will offer virtual access for worldwide attendees.

Product News
LGM Pharma Invests $6M in U.S. Drug Manufacturing Capabilities
LGM Pharma announces a $6M investment to expand its Rosenberg, Texas facility, enhancing its capacity for liquid, semi-solid and suppository drug production. The expansion supports growing prescription drug demand.

Product News
Lyndra Therapeutics Announces Strategic Clinical Research and Commercial Manufacturing Services Collaboration With Thermo Fisher Scientific for Long-Acting Oral Therapies
Lyndra Therapeutics, a clinical-stage biopharmaceutical company, announced a strategic collaboration with Thermo Fisher Scientific Inc.

Product News
ABITEC Unveils Comprehensive Custom Lipid Synthesis Capabilities for LNP Therapeutics
LNP developers now have access to bench-to-patient lipid synthesis support from a single partner.

Product News
New Scientific Advisory Board Members
Aptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life sciences industry, is pleased to announce three new members to its Scientific Advisory Board (SAB).

Product News
Thermo Fisher Scientific Introduces Invitrogen™ Vivofectamine™ Delivery Solutions To Help Advance Life Science Research and Genetic Medicines
Thermo Fisher Scientific has introduced the Invitrogen Vivofectamine™ Delivery Solutions to provide high-performance lipid nanoparticles (LNP) technology for non-viral delivery of nucleic acids.

Product News
Aptamer Extends Agreement With Genetic Medicines Customer
Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders, is pleased to announce that a genetic medicines customer has selected to progress to the final commercial development phase for Optimer delivery vehicles.

Product News
Evotec and Bristol Myers Squibb Expand Proteomics Partnership
Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced progress within the Company’s strategic partnership with Bristol Myers Squibb relating to building a molecular glue-based pipeline.

Product News
Lonza Extends Collaboration With Major Pharmaceutical Partner for Integrated Commercial Supply of Antibody-Drug Conjugates
Lonza, announced a long-term extension of its collaboration with a major global biopharmaceutical partner for commercial-scale manufacture of ADCs.
Advertisement